NDA 020758 · Sanofi Aventis US
Avalide
Hydrochlorothiazide, Irbesartan · Oral · Thiazide Diuretic; Angiotensin 2 Receptor Blocker
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 30, 1997
Approved uses
2
Original approval plus efficacy supplements
Registered trials
450
138 Phase 3, 14 recruiting
FAERS reports
5,317
3,023 serious, 277 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue AVALIDE as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue AVALIDE as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )
What it is approved for
From the label in effect Oct 7, 2025.
AVALIDE ® (irbesartan and hydrochlorothiazide) tablets are indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or hydrochlorothiazide (HCTZ) monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP <140 or <130 mmHg or SeDBP <90 or <80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP <140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7) For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). Figure 1b: Probability of Achieving SBP <130 mmHg in Patients from Initial...
Mechanism: Irbesartan Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT 1 angiotensin II receptor. There is also an AT 2 receptor in...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 16, 2007 Supplement 37 · Efficacy LabelLetter
- Sep 30, 1997 Original approval · Type 4 - New Combination Review
4 products under this application
- AVALIDE · HYDROCHLOROTHIAZIDE 25MG; IRBESARTAN 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- AVALIDE · HYDROCHLOROTHIAZIDE 12.5MG; IRBESARTAN 150MG · TABLET, ORAL · Prescription · TE AB
- AVALIDE · HYDROCHLOROTHIAZIDE 12.5MG; IRBESARTAN 300MG · TABLET, ORAL · Prescription · TE AB
- AVALIDE · HYDROCHLOROTHIAZIDE 12.5MG; IRBESARTAN 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.
- INVEST: INternational VErapamil SR Trandolapril STudyPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT00133692 · 22,000 participants · Start Sep 1997
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Atenolol/HCTZ/Trandolapril · For: Hypertension; Coronary Artery Disease
Sites: Gainesville, Florida
- Diuretic Comparison ProjectPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT02185417 · 20,723 participants · Start Jun 15, 2016 · Primary completion Oct 15, 2022
Drug: Hydrochlorothiazide (HCTZ); Chlorthalidone (CTD) · For: Hypertension
Sites: Birmingham, Alabama; Anchorage, Alaska; Fayetteville, Arkansas · 70 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01271985 · 8,410 participants · Start Feb 2011 · Primary completion Jan 2019
Drug: PolyPill · For: Cardiovascular Diseases
Sites: Gonbad, Iran
- Strategy of Blood Pressure Intervention in the Elderly Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT03015311 · 8,000 participants (planned) · Start Jan 15, 2017 · Primary completion Dec 31, 2020
Drug: Intensive BP control; Standard BP control · For: Primary Hypertension
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 42 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea352
- dizziness338
- fatigue308
- drug ineffective298
- dyspnoea246
- headache244
- blood pressure increased217
- diarrhoea216
- hypertension202
- pain195
- vomiting192
- asthenia186
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 198 |
| 2005 | 271 |
| 2006 | 304 |
| 2007 | 310 |
| 2008 | 351 |
| 2009 | 400 |
| 2010 | 475 |
| 2011 | 742 |
| 2012 | 402 |
| 2013 | 174 |
| 2014 | 165 |
| 2015 | 175 |
| 2016 | 188 |
| 2017 | 137 |
| 2018 | 182 |
| 2019 | 252 |
| 2020 | 128 |
| 2021 | 99 |
| 2022 | 113 |
| 2023 | 73 |
| 2024 | 74 |
| 2025 | 65 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Avalide (Irbesartan/Hydrochlorothiazide)
2024 spending
$730K
Beneficiaries
283
1,141 claims
Per beneficiary
$2,580
$9.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,577,434 |
| 2021 | $1,371,162 |
| 2022 | $1,176,908 |
| 2023 | $1,080,180 |
| 2024 | $730,097 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Ishani A, Cushman WC, Leatherman SM, et al. · N Engl J Med 2022 · Comparative Study, Pragmatic Clinical Trial
- Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
Dhayat NA, Bonny O, Roth B, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.
Roush GC, Ernst ME, Kostis JB, et al. · Hypertension 2015 · Meta-Analysis, Systematic Review
- Oslo Hypertension Study.
Leren P, Helgeland A · Drugs 1986 · Clinical Trial, Randomized Controlled Trial
- Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K, Weber MA, Bakris GL, et al. · N Engl J Med 2008 · Comparative Study, Multicenter Study
- Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension: A Secondary Analysis of a Randomized Clinical Trial.
Ishani A, Hau C, Raju S, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.